The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)
- Citation:
- Blood vol 122 (21) Abstract 2882
- Meeting Instance:
- ASH 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2424
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Wei Ding Tait D. Shanafelt Clive S. Zent Jose F. Leis Betsy R. LaPlant Timothy G. Call Curtis A. Hanson Charles Erlichman Thomas M. Habermann Craig Reeder Daniel Nikcevich Deborah Bowen Michael J. Conte Justin Boysen Charla Secreto Connie Lesnick Renee C. Tschumper Diane F. Jelinek Neil E. Kay
- Networks:
- ESSENTIA, LAPS-MN026
- Study
- NCCTG-N1087
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: